SG Americas Securities LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

SG Americas Securities LLC increased its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 48.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,070 shares of the company’s stock after buying an additional 5,906 shares during the period. SG Americas Securities LLC’s holdings in Phathom Pharmaceuticals were worth $165,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in PHAT. Quantbot Technologies LP lifted its holdings in Phathom Pharmaceuticals by 112.6% in the 2nd quarter. Quantbot Technologies LP now owns 5,527 shares of the company’s stock valued at $46,000 after purchasing an additional 2,927 shares in the last quarter. Legal & General Group Plc lifted its holdings in Phathom Pharmaceuticals by 20.1% in the 2nd quarter. Legal & General Group Plc now owns 6,328 shares of the company’s stock valued at $54,000 after purchasing an additional 1,061 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in Phathom Pharmaceuticals by 2,715.2% in the 2nd quarter. Osaic Holdings Inc. now owns 4,251 shares of the company’s stock valued at $59,000 after purchasing an additional 4,100 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Phathom Pharmaceuticals by 371.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,429 shares of the company’s stock valued at $87,000 after purchasing an additional 6,641 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new position in Phathom Pharmaceuticals in the 2nd quarter valued at about $87,000. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a report on Thursday, April 11th.

Insider Activity

In other news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the completion of the transaction, the insider now owns 3,755,583 shares of the company’s stock, valued at approximately $30,420,222.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO Molly Henderson sold 3,435 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $11.10, for a total transaction of $38,128.50. Following the completion of the sale, the chief financial officer now owns 95,263 shares of the company’s stock, valued at approximately $1,057,419.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the sale, the insider now directly owns 3,755,583 shares of the company’s stock, valued at approximately $30,420,222.30. The disclosure for this sale can be found here. Insiders sold a total of 3,730,296 shares of company stock valued at $30,240,515 in the last 90 days. 7.50% of the stock is currently owned by insiders.

Phathom Pharmaceuticals Price Performance

NASDAQ PHAT opened at $10.02 on Tuesday. Phathom Pharmaceuticals, Inc. has a 12 month low of $6.07 and a 12 month high of $17.02. The company has a 50-day moving average of $9.44 and a 200-day moving average of $8.74. The company has a market cap of $585.97 million, a P/E ratio of -2.58 and a beta of 0.63.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.12. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.93 million. During the same period in the prior year, the company earned ($1.33) EPS. As a group, equities research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.22 EPS for the current year.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.